Skip to main content
Full access
Letter to the Editor
Published Online: 1 March 2010

Psychosis Following Excessive Ingestion of Energy Drinks in a Patient With Schizophrenia

To the Editor: Caffeine can induce psychosis in healthy people (1) and worsen psychotic symptoms in individuals with psychotic disorders (2, 3). We describe a patient with schizophrenia who experienced psychotic decompensation while using energy drinks.
"Mr. C" was a 43-year-old man with schizophrenia, paranoid type, and alcohol dependence, in full sustained remission, who presented with a 6-week history of progressively worsening paranoia, religious delusions, and agitation.
The patient had been stable and without hospitalization for several years. He was managed with haloperidol decanoate injections (150 mg every 4 weeks). He had not used alcohol for 30 months, had intermittently used cannabis and cocaine in his early twenties (with no recent use, confirmed by negative toxicology analysis), and did not previously use caffeine or cigarettes.
The patient began drinking energy drinks 8 weeks prior to presentation. He reported feeling increased interest in activities and improved mood after drinking his first can of the drink, subsequently increasing his daily consumption up to eight to 10 cans (16 oz per can) daily.
Mr. C displayed paranoia, internal preoccupations, constricted affect, and delusional religious beliefs. He was hospitalized; his consumption of caffeine was ceased; and no new antipsychotic treatments were prescribed. Ten days later, he was better related, less paranoid, and calmer, with diminished religious delusions. He was discharged from the hospital while taking haloperidol decanoate (150 mg), with appropriate follow-up appointments.
Caffeine functions in the central nervous system as a competitive antagonist of adenosine receptors, A1 and A2A, and alters neurotransmitter release, including dopamine and glutamate. This dopamine release in the striatum may underlie caffeine's reinforcing properties, and the modulation of the mesolimbic dopamine pathway may be related to its psychotomimetic effect (1). Exaggerated effects may be seen in patients with schizophrenia using high-dose caffeine (2). The energy drink the patient in the present case consumed contained 160 mg of caffeine per can. The patient weighed 67 kg and therefore consumed approximately 20 mg/kg per day of caffeine. Psychosis has been reported at doses near 10 mg/kg per day (3), which is well below the known toxic dosage (150–200 mg/kg) but above the average intake by the numerous schizophrenia outpatients who use caffeine (1.8–4.1 mg/kg per day [depending on smoking status]) (4).
Although we cannot definitively demonstrate a causal relationship between the use of energy drinks and psychotic decompensation, the temporal association is convincing. The patient in our case adhered with pharmacotherapy and had no recent stressor. He improved with supportive care in a controlled environment and without pharmacological intervention, a course consistent with caffeine-induced psychosis.

References

1.
Hedges DW, Woon FL, Hoopes SP: Caffeine-induced psychosis. CNS Spectr 2009; 14:127–129
2.
Lucas PB, Pickar D, Kelsoe J, Rapaport M, Pato C, Hommer D: Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 1990; 28:35–40
3.
Caykoylu A, Ekini O, Murat A: Improvement from treatment-resistant schizoaffective disorder, manic type after stopping heavy caffeine intake: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1349–1350
4.
Gurpegui M, Aguilar MC, Martinez-Ortega JM, Jurado D, Diaz FJ, Quintana HM, de Leon J: Fewer but heavier caffeine consumers in schizophrenia: a case-control study. Schizophr Res 2006; 86:276–283

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 353
PubMed: 20194494

History

Accepted: December 2009
Published online: 1 March 2010
Published in print: March 2010

Authors

Affiliations

Joseph M. Cerimele, M.D.
Didier Jutras-Aswad, M.D.

Competing Interests

The authors report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share